Wiggins Kathryn J, Tiauw Victoria, Zhang Yuan, Gilbert Richard E, Langham Robyn G, Kelly Darren J
Department of Medicine, The University of Melbourne, St Vincent's Hospital, Melbourne, Victoria, Australia.
Nephrology (Carlton). 2008 Dec;13(8):721-9. doi: 10.1111/j.1440-1797.2008.01008.x. Epub 2008 Sep 25.
Renal hypoxia plays a role in the development of diabetic nephropathy, and may be mediated by overactivity of the renin-angiotensin-aldosterone system (RAAS). In this study the localization of cellular hypoxia in an experimental model of diabetic nephropathy was assessed, and the effect of the angiotensin-converting enzyme inhibitor perindopril on hypoxia evaluated.
Female Sprague-Dawley rats heterozygous for the Ren-2 gene were randomized to three groups (n = 8 per group)--controls, diabetes or diabetes + perindopril. Diabetes was induced by injection of streptozotocin at 6 weeks of age. Perindopril was administered at a dose of 2 mg/kg daily from 6 weeks. Subjects were culled after 16 weeks. Areas of tissue hypoxia were localized using immunohistochemistry to detect pimonidazole uptake.
Diabetic rat kidneys were characterized by increases in tubulointerstitial collagen deposition compared with controls. Tubular hypoxia was significantly greater in diabetic rats, indicated by a 2.5-fold increase in the proportional area of pimonidazole immunostaining (P < 0.001). Immunohistochemical staining for pimonidazole co-localized with osteopontin, and was associated with higher numbers of ED-1-positive cells (macrophages) within the tubulointerstitium. Treatment with perindopril ameliorated structural changes of diabetic nephropathy and reduced the amount of pimonidazole and ED-1 immunostaining to levels similar to that of controls.
In diabetic Ren-2 rats the development of diabetic nephropathy was associated with tubular hypoxia. Co-localization of osteopontin with hypoxic cells suggests that tubular hypoxia may be involved in the pathogenesis of diabetic nephropathy. The degree of hypoxia and fibrosis was attenuated by treatment with perindopril.
肾脏缺氧在糖尿病肾病的发展中起作用,可能由肾素 - 血管紧张素 - 醛固酮系统(RAAS)过度激活介导。本研究评估了糖尿病肾病实验模型中细胞缺氧的定位,并评估了血管紧张素转换酶抑制剂培哚普利对缺氧的影响。
将杂合Ren - 2基因的雌性Sprague - Dawley大鼠随机分为三组(每组n = 8)——对照组、糖尿病组或糖尿病 + 培哚普利组。6周龄时通过注射链脲佐菌素诱导糖尿病。从6周起每天以2 mg/kg的剂量给予培哚普利。16周后处死动物。使用免疫组织化学检测匹莫硝唑摄取来定位组织缺氧区域。
与对照组相比,糖尿病大鼠肾脏的特征是肾小管间质胶原沉积增加。糖尿病大鼠的肾小管缺氧明显更严重,匹莫硝唑免疫染色的比例面积增加2.5倍表明了这一点(P < 0.001)。匹莫硝唑的免疫组织化学染色与骨桥蛋白共定位,并且与肾小管间质内ED - 1阳性细胞(巨噬细胞)数量增加有关。培哚普利治疗改善了糖尿病肾病的结构变化,并将匹莫硝唑和ED - 1免疫染色量降低至与对照组相似的水平。
在糖尿病Ren - 2大鼠中,糖尿病肾病的发展与肾小管缺氧有关。骨桥蛋白与缺氧细胞的共定位表明肾小管缺氧可能参与糖尿病肾病的发病机制。培哚普利治疗减轻了缺氧和纤维化程度。